2123 POSTER MO19391: an open-label safety study of bevacizumab plus taxane monotherapy or in combination as first-line treatment of patients with locally recurrent or metastatic breast cancer (LR or MBC)
2007 ◽
Vol 5
(4)
◽
pp. 221
◽
Keyword(s):
2008 ◽
Vol 26
(15_suppl)
◽
pp. 1140-1140
◽
Keyword(s):
2014 ◽
Vol 32
(15_suppl)
◽
pp. 635-635